The Filing Desk

Arbutus Biopharma

ABUS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

ABUS · Last close · November 13, 2026
$4.09
Value Arbutus Biopharma yourself

Arbutus Biopharma's revenue rose 128.2% to $14 million in fiscal 2025. Its operating margin was −271.0%, up from −1,236.7% a year earlier. Free cash flow was −$40 million. The diluted share count rose 3.2%.

ARBUTUS BIOPHARMA CORP Latest fiscal year ended December 31, 2025 10-K filed March 23, 2026 · 0001447028-26-000017 Updated
Revenue
$14M
128.2%
Operating margin
−271.0%
965.8 pts
Net income
−$34M
 
Free cash flow
−$40M
 
Return on equity
−38.5%
30.2 pts
Market cap
$816M
Nov 13 close
P/E
3.6x
On $1.13 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Arbutus Biopharma does

Arbutus Biopharma is a clinical-stage drug developer focused on infectious disease. Clinical-stage means its medicines are still being tested in people and none is approved for sale. Its two main candidates are imdusiran, an injected RNA-based treatment, and AB-101, an oral pill, both aimed at chronic hepatitis B, a long-lasting liver infection.

The company has no product sales and says it has had operating losses in nearly every year since it started. Its income comes from licensing its delivery technology, which wraps genetic material in tiny fat-based particles so it can reach cells in the body. It licenses this technology through Genevant, a company in which it owns about 16%, and it is suing Pfizer and BioNTech over their use of it in COVID-19 vaccines. In March 2026 it settled with Moderna, which agreed to pay $950.0 million up front to Arbutus and Genevant together, with more possible later. Arbutus is entitled to 20% of that up-front payment after litigation costs. It also holds a royalty right tied to Alnylam's drug ONPATTRO.

In 2024 and 2025 Arbutus cut its staff sharply, replaced its board and chief executive, closed its Pennsylvania headquarters and stopped in-house research to focus on the hepatitis B programs.

Its biggest risks, as it describes them

  • Losing or failing to win its patent lawsuits against large companies such as Pfizer and BioNTech, which cost a lot to pursue.
  • The extra Moderna payment depends on a favorable ruling in a limited appeal, and may never be paid.
  • Its hepatitis B candidates are early-stage and may not prove safe or effective or win approval.
  • It has no product revenue, has lost money in nearly every year and may need more capital.
  • The FDA has placed a clinical hold on its AB-101 application, which may take time to lift.
From Arbutus Biopharma's annual report on Form 10-K, filed March 23, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Arbutus Biopharma lost money in fiscal 2025: a net loss of $34 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments19118413212392
Debt incl. finance leases00000
Net debt (negative means net cash)−191−184−132−123−92
Net debt to EBITDA—————
Debt to equity0.0x0.0x0.0x0.0x0.0x
Interest coverage−25.7x−37.9x−170.2x−557.1x−393.4x
Current ratio14.3x4.6x5.9x8.2x15.7x
Quick ratio14.3x4.6x5.9x8.2x15.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Arbutus Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Arbutus Biopharma reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 82 of 83 of 8
Rule of 40−532.8%−1,119.8%−153.2%
Altman Z''−24.58−28.68−39.67
Accruals ratio7.7%−3.7%5.4%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailPass
Cash from operations exceeds net incomeFailPassFail
Debt fell relative to assetsFailFailFail
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsFailFailPass
F-score1 of 82 of 83 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Arbutus Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Arbutus BiopharmaFY25128.2%−271.0%−281.4%——3
Relay TherapeuticsFY2553.4%−1,971.6%−1,536.1%———Compare
Janux TherapeuticsFY25−5.5%−1,576.7%−832.8%———Compare
Taysha Gene TherapiesFY2517.3%−1,130.7%−960.1%——4Compare
Roivant SciencesFY25−71.6%−6,235.7%−9,183.5%−62.6%—1Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue211667113918614
Revenue growth−93.6%617.6%−44.4%1.1%15.0%58.9%255.1%−53.5%−66.0%128.2%
Gross profit——————————
Research and development61635858496684745425
Operating income−492−111−90−144−58−74−66−78−76−38
Net income−384−84−57−154−64−76−70−73−70−34
Diluted EPS (US$)−7.24−1.56−1.21−2.89−1.00−0.83−0.46−0.44−0.38−0.17
Diluted shares (millions)5355555776106151166186192
Cash flow
Cash from operations−58−49−68−71−51−68−35−86−65−40
Capital expenditure4711010100
Free cash flow−62−56−69−72−52−68−36−87−65−40
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation391567667997
Balance sheet at fiscal year end
Cash and short-term investments1311261259112319118413212392
Debt incl. finance leases—————00000
Total assets27623722810613720419514413295
Total liabilities73552833353559383418
Shareholders' equity203182200731021691371069777
Margins and ratios
Gross margin——————————
Operating margin−32,973.8%−1,036.7%−1,510.2%−2,394.0%−836.1%−669.1%−167.8%−430.5%−1,236.7%−271.0%
Net margin−25,765.5%−788.9%−959.8%−2,557.4%−922.0%−693.9%−178.0%−401.6%−1,133.0%−237.9%
Free cash flow margin−4,150.3%−522.5%−1,160.7%−1,191.1%−747.3%−622.0%−91.9%−479.3%−1,053.8%−281.4%
Rule of 40 (growth + FCF margin)−4,243.9%95.2%−1,205.2%−1,190.0%−732.3%−563.0%163.2%−532.8%−1,119.8%−153.2%
Return on capital——————————
Return on equity−102.3%−43.8%−29.8%−112.6%−73.0%−56.2%−45.4%−60.0%−68.8%−38.5%
Return on assets−77.8%−32.9%−24.5%−92.2%−52.5%−44.6%−34.7%−42.9%−50.6%−29.6%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Arbutus Biopharma's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Arbutus Biopharma.